Larimar Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
666
across all filing types
Latest filing
2023-08-10
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2023-08-10 | English | |
| 8-K | 2023-08-10 | English | |
| 8-K | 2023-07-25 | English | |
| Regulatory Filings 2023 | 2023-07-24 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2023-07-18 | English | |
| INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 2023-07-18 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 12034578 | 10-Q | 2023-08-10 | English | ||
| 12034581 | 8-K | 2023-08-10 | English | ||
| 12034586 | 8-K | 2023-07-25 | English | ||
| 12034587 | Regulatory Filings 2023 | 2023-07-24 | English | ||
| 12034588 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2023-07-18 | English | ||
| 12034592 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 2023-07-18 | English | ||
| 12034589 | 8-K | 2023-07-17 | English | ||
| 12034593 | 8-K | 2023-06-01 | English | ||
| 12034594 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2023-05-18 | English | ||
| 12034595 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2023-05-18 | English | ||
| 12034596 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2023-05-18 | English | ||
| 12034599 | 10-Q | 2023-05-15 | English | ||
| 12034605 | 8-K | 2023-05-15 | English | ||
| 12034606 | 8-K | 2023-05-12 | English | ||
| 12034600 | Director's Dealing 2023 | 2023-05-11 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Larimar Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33359/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33359 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33359 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33359 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33359}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Larimar Therapeutics, Inc. (id: 33359)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.